195 related articles for article (PubMed ID: 7517763)
41. The prognostic significance of the cytophotometric DNA content and its relationship with the argyrophilic nucleolar organizer regions (AgNOR) and proliferating cell nuclear antigen (PCNA) in oesophageal cancer.
Kuwano H; Sumiyoshi K; Nozoe T; Yasuda M; Watanabe M; Sugimachi K
Eur J Surg Oncol; 1995 Aug; 21(4):368-73. PubMed ID: 7664900
[TBL] [Abstract][Full Text] [Related]
42. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients.
Ishida T; Kaneko S; Akazawa K; Tateishi M; Sugio K; Sugimachi K
Cancer Res; 1993 Oct; 53(20):5000-3. PubMed ID: 8104690
[TBL] [Abstract][Full Text] [Related]
43. [Expression of PCNA and the count of AgNOR in squamous cell carcinoma of larynx and hypopharynx].
Zheng M; Tian X; Li H; Cheng Y; Chen X
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Dec; 16(12):653-5. PubMed ID: 12669433
[TBL] [Abstract][Full Text] [Related]
44. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
Bethwaite PB; Delahunt B; Holloway LJ; Thornton A
Pathology; 1995 Jan; 27(1):1-4. PubMed ID: 7603742
[TBL] [Abstract][Full Text] [Related]
45. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
46. Proliferating cell nuclear antigen and argyrophilic nucleolar organizer regions in patients with thymic disease.
Oyama T; Osaki T; Mitsudomi T; Mizoue T; Ohgami A; Nakanishi R; Sugio K; Yasumoto K
Oncol Rep; 1997; 4(6):1201-5. PubMed ID: 21590222
[TBL] [Abstract][Full Text] [Related]
47. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
48. High and low risk prostate carcinoma determined by histologic grade and proliferative activity.
Chiusa L; Galliano D; Formiconi A; Di Primio O; Pich A
Cancer; 1997 May; 79(10):1956-63. PubMed ID: 9149023
[TBL] [Abstract][Full Text] [Related]
49. [Significance of FCM-DNA ploidy pattern, AgNOR counting, hTERT and PCNA expression in differentiating malignant from benign serous effusion].
Wu LY; Liu BR; Lu J; Ling MD; Chen J; Li P; Jiang Y
Ai Zheng; 2007 Feb; 26(2):178-82. PubMed ID: 17298749
[TBL] [Abstract][Full Text] [Related]
50. Nucleolar organizer regions in the fine needle aspirates of lung tumours.
Ascoli V; Barsotti P; Facciolo F; Nardi F; Marinozzi V
Cytopathology; 1990; 1(5):277-86. PubMed ID: 1714309
[TBL] [Abstract][Full Text] [Related]
51. An improved system for quantifying AgNOR and PCNA in canine tumors.
Hung LC; Pong VF; Cheng CR; Wong FI; Chu RM
Anticancer Res; 2000; 20(5A):3273-80. PubMed ID: 11062753
[TBL] [Abstract][Full Text] [Related]
52. Studies on morphological typing of argyrophilic nucleolar organizer regions.
Xu LZ; Zhu WP; Chen G
Pathol Int; 1995 Nov; 45(11):860-5. PubMed ID: 8581149
[TBL] [Abstract][Full Text] [Related]
53. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
[TBL] [Abstract][Full Text] [Related]
54. Argyrophilic nucleolar organizer region counts and Ki-67 scores in human renal cell carcinoma.
Pich A; Valente G; Azzoni L; Stramignoni A; Margaria E; Tasso M
Pathol Res Pract; 1991 May; 187(4):482-6. PubMed ID: 1715079
[TBL] [Abstract][Full Text] [Related]
55. Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumour grade, mitotic index, and silver-staining nucleolar organizer region numbers.
Delahunt B; Bethwaite PB; Nacey JN; Ribas JL
J Pathol; 1993 Aug; 170(4):471-7. PubMed ID: 8105046
[TBL] [Abstract][Full Text] [Related]
56. PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis.
Morisaki Y; Shima S; Yoshizumi Y; Sugiura Y; Tanaka S; Tamai S
Surg Today; 1995; 25(5):389-95. PubMed ID: 7640465
[TBL] [Abstract][Full Text] [Related]
57. Multiparameter analysis of AgNOR in thyroid lesions: comparison with PCNA expression.
Slowińska-Klencka D; Klencki M; Popowicz B; Sporny S; Lewiński A
Histol Histopathol; 2004 Jul; 19(3):785-92. PubMed ID: 15168341
[TBL] [Abstract][Full Text] [Related]
58. Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters.
Skopelitou A; Korkolopoulou P; Papanicolaou A; Christodoulou P; Thomas-Tsagli E; Pavlakis K
Eur Urol; 1992; 22(3):235-40. PubMed ID: 1361436
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors in urachal adenocarcinoma. A study in 41 specimens of DNA status, proliferating cell-nuclear antigen immunostaining, and argyrophilic nucleolar-organizer region counts.
Nakanishi K; Kawai T; Suzuki M; Torikata C
Hum Pathol; 1996 Mar; 27(3):240-7. PubMed ID: 8600037
[TBL] [Abstract][Full Text] [Related]
60. The prognostic significance of AgNOR counts and PCNA-positive cell counts in canine malignant lymphomas.
Kiupel M; Bostock D; Bergmann V
J Comp Pathol; 1998 Nov; 119(4):407-18. PubMed ID: 9839202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
